An observational study in Hepatocellular Carcinoma and Liver Cancer, sponsored by Asan Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.
Sponsored by Asan Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Carcinoma, Hepatocellular by Asan Medical Center — 5 open to participants now, 7 under way, none of them phase 3. Carcinoma, Hepatocellular · Asan Medical Center.
Among the 20 studies in Carcinoma, Hepatocellular by Asan Medical Center, this one is one of 2 that started in 2020, is one of 6 observational ones, and was the 19th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →5 of the 20 studies in Carcinoma, Hepatocellular by Asan Medical Center are open now, in 1 country. Recruiting first, the newest first:
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
Asan Medical Center · Sites in Korea, Republic of
Ages 19–80
Asan Medical Center · Sites in Korea, Republic of
Ages 20+
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 1
First in 2008; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 60 across the 14 interventional studies, 200 across the 6 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
Asan Medical Center is the lead sponsor of 578 studies on the registry; 72 are open to participants now.
3 of the studies in Carcinoma, Hepatocellular by Asan Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186010Asan Medical CenterImmunogenomic Dynamics and Biomarkers in Patients With Hepatocellular Carcinoma Receiving Immunotherapy | 2026-12-31 |
| NCT06819566Asan Medical CenterProphylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC | 2026-12-31 |
| NCT06537193Asan Medical CenterAbbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Carcinoma, Hepatocellular by Asan Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
2) Fresh tumors will be stored in the tissue obtained during the biopsy to perform genetic analysis
This study is designed to perform comprehensive genomic and immune profiling in patients with advanced hepatocellular carcinoma (HCC) undergoing immuno-oncology (IO) treatment. The objective is to investigate molecular and immunologic biomarkers in both blood and tumor tissue that may correlate with treatment response, disease progression, and clinical outcomes.
Eligible patients include those with recurrent, metastatic, or advanced HCC who are scheduled to receive IO therapy and who meet the study's inclusion and exclusion criteria. Approximately 50 participants will be enrolled.
Peripheral blood samples will be collected at predefined time points: prior to initiation of IO treatment (baseline), and at 6, 12, 24, and 48 weeks after treatment initiation, as well as at the time of disease progression. These blood samples will be subjected to genomic and immune profiling, including but not limited to circulating tumor DNA analysis, immune cell subset characterization, and cytokine/chemokine profiling.
In addition, fresh tumor tissue obtained from biopsy procedures will be stored and used for genetic and immunologic analyses. Tissue-based studies may include next-generation sequencing, immunohistochemistry, multiplex immunofluorescence, and other exploratory assays to evaluate tumor mutational landscape, immune checkpoint expression, and tumor microenvironmental features.
By integrating longitudinal blood-based biomarkers with tumor tissue data, this study aims to better characterize tumor biology, immune dynamics, and mechanisms of resistance in advanced HCC treated with immuno-oncology agents. The ultimate goal is to identify predictive and prognostic biomarkers that may guide personalized treatment strategies and improve clinical outcomes in this patient population.
Patients with histologically confirmed recurrent, locally advanced or metastatic HCC who will receive immuno-oncology treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Objective response rate (ORR) according to RECIST 1.1 criteria
Proportion of participants achieving complete response (CR) or partial response (PR) as their best overall response, assessed by imaging according to RECIST 1.1 criteria.
Time frame: from the date of the first immunotherapy date', every 9 weeks, for 2 years
overall survival
overall survival after initiation of immunotherapy
Time frame: From date of immunotherapy until the date of death from any cause or study end whichever came first, assessed up to assessed up to 5 years
Started Sep 2020 (actual). Primary completion is estimated for Dec 2026, 75 months after the start.
Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 75 months is above that.
Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.